Biodesix, Inc. (NASDAQ:BDSX) Insider Sells $15,408.16 in Stock

Biodesix, Inc. (NASDAQ:BDSX) insider Gary Anthony Pestano sold 16,748 shares of the company’s stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $0.92, for a total value of $15,408.16. Following the completion of the transaction, the insider now directly owns 156,008 shares of the company’s stock, valued at approximately $143,527.36. This represents a 9.69 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Biodesix Stock Performance

BDSX stock opened at $0.99 on Friday. The business has a 50 day moving average of $1.23 and a 200-day moving average of $1.48. Biodesix, Inc. has a 12-month low of $0.86 and a 12-month high of $2.04. The firm has a market cap of $143.29 million, a PE ratio of -2.53 and a beta of 1.06. The company has a quick ratio of 3.40, a current ratio of 3.40 and a debt-to-equity ratio of 1.30.

Hedge Funds Weigh In On Biodesix

Several institutional investors and hedge funds have recently bought and sold shares of BDSX. Wilmington Savings Fund Society FSB bought a new position in Biodesix during the third quarter valued at $10,849,000. Samjo Management LLC bought a new position in Biodesix during the fourth quarter valued at $3,790,000. Susquehanna International Group LLP grew its holdings in Biodesix by 769.8% during the fourth quarter. Susquehanna International Group LLP now owns 1,115,748 shares of the company’s stock valued at $1,707,000 after purchasing an additional 987,475 shares during the period. Silverarc Capital Management LLC grew its holdings in Biodesix by 21.7% during the fourth quarter. Silverarc Capital Management LLC now owns 4,332,281 shares of the company’s stock valued at $6,628,000 after purchasing an additional 771,187 shares during the period. Finally, AIGH Capital Management LLC grew its holdings in Biodesix by 8.8% during the fourth quarter. AIGH Capital Management LLC now owns 6,179,812 shares of the company’s stock valued at $9,455,000 after purchasing an additional 500,000 shares during the period. 20.96% of the stock is owned by institutional investors.

Biodesix Company Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.